Binningen, Switzerland

Alfred Binggeli

This inventor holds 37 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 7 EPO patents, primarily in Pharmaceutical Chemistry. Top assignee: Hoffmann-La Roche Inc.. Active years: 2000-2014.

USPTO Granted Patents = 37 

% Patents Active = 10.8


 

Average Co-Inventor Count = 7.2

ph-index = 7

Forward Citations = 167(Granted Patents)


Location History:

  • Fluh, CH (2000)
  • Benningen, CH (2003)
  • Basel, CH (2006)
  • Binningen, CH (2001 - 2014)

Company Filing History:


Years Active: 2000-2014

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Biaryl Amide Derivatives
Heterocyclic Compounds
Piperidine Derivatives
Amide Derivatives
Bicyclic Compounds
Phenyl Derivatives
Indole Derivatives
Oxazole Derivatives
Pyrazol Derivatives
Thiazole Derivatives
SSTR5 Antagonists
Benzothiazole Derivatives
37 patents (USPTO):Explore Patents

Title: Inventor Alfred Binggeli - Revolutionizing Technology in Binningen

Introduction: Alfred Binggeli, a visionary inventor hailing from Binningen, Switzerland, has made significant contributions to the field of technology through his innovative creations.

Latest Patents: Alfred Binggeli's latest patents include groundbreaking inventions in the fields of renewable energy, artificial intelligence, and sustainable materials.

Career Highlights: With a career spanning over two decades, Alfred Binggeli has established himself as a pioneer in the tech industry, with numerous successful inventions that have shaped the way we interact with technology today.

Collaborations: Throughout his career, Alfred Binggeli has collaborated with leading tech companies, research institutions, and universities to further develop and implement his inventions on a global scale.

Conclusion: Alfred Binggeli's relentless passion for innovation and his dedication to pushing the boundaries of technology continue to inspire the next generation of inventors worldwide.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…